Ricerca CERCA

Advanced monitoring of chronic wound healing upon treatment with an innovative therapeutic agent

azienda Thesis in external company    



Research Groups 05-Bioingegneria Industriale

Description Despite great efforts have been devoted in the field of wound healing-related applications, the successful management of hard-to-heal skin wounds is still highly challenging. The main aspects responsible for this situation lies in (i) the absence of advanced treatments able to effectively interact with the wound bed environment and promote tissue regeneration and (ii) the lack of objective methods to monitor the progression of the wound status upon treatments.

In this context, by exploiting an interdisciplinary approach gathering the Politecnico di Torino and two national and international companies (Omnidermal Biomedics (Italy) and FROXIMUN AG (Germany)), we are working on the establishment of innovative approaches able to face both these critical aspects. Specifically, from one side we are developing a smart drug delivery system able to encapsulate an inorganic powder as novel therapeutic agent and control its release through a wound-triggered stimulus (e.g., the alkalinity of infected wound exudate). On the other side, relying on the technology already established by Omnidermal Biomedics, we are exploiting artificial intelligence approaches to objectively measure and monitor wound closure.

In the framework of this project, the proposed master’s thesis has been conceived to combine informatics and biological skills. Specifically, the work will be initially focused on the software counterpart at Omnidermal Biomedics (Politecnico di Torino) and then, on the validation of its capability to monitor and provide objective data on wound regeneration at lab scale at Biomedical Laboratory (Alessandria). To this purpose, 2D and 3D in vitro assays will be performed by using dermal fibroblasts cultured in normal and pathological conditions. Specifically, a wound-mimicking environment will be first recreated, then cells will be treated with the inorganic powder provided by FROXIMUM AG as novel therapeutic agent and lastly, fibroblast capability to restore the cell layer will be monitored and assessed through both traditional methods (e.g., immunofluorescence) and the approach developed at Omnidermal Biomedics.

Required skills Requisite: max. 2 exams left

Notes Locations and duration: Omnidermal Biomedics (Turin, 50%)/ Biomedical Lab di Alessandria (50%), May 2024 – March 2025

Deadline 16/04/2025      PROPONI LA TUA CANDIDATURA

© Politecnico di Torino
Corso Duca degli Abruzzi, 24 - 10129 Torino, ITALY